...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast cancer research and treatment. >Vaccination for the prevention and treatment of breast cancer with special focus on Her-2eu peptide vaccines
【24h】

Vaccination for the prevention and treatment of breast cancer with special focus on Her-2eu peptide vaccines

机译：预防和治疗乳腺癌的疫苗，特别关注Her-2 / neu肽疫苗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunologic interventions in a subset of breast cancer patients represent a well-established therapeutic approach reflecting individualized treatment modalities. Thus, the therapeutic administration of monoclonal antibodies targeting tumor-associated antigens (TAA), such as Her-2eu, represents a milestone in cancer treatment. However, passive antibody administration suffers from several drawbacks, including frequency and long duration of treatment. These undesirables may be avoidable in an approach based on generating active immune responses against these same targets. Only recently has the significance of tumors in relation to their microenvironments been understood as essential for creating an effective cancer vaccine. In particular, the immune system plays an important role in suppressing or promoting tumor formation and growth. Therefore, activation of appropriate triggers (such as induction of Th1 cells, CD8+ T cells, and suppression of regulatory cells in combination with generation of antibodies with anti-tumor activity) is a desirable goal. Current vaccination approaches have concentrated on therapeutic vaccines using certain TAA. Many cancer antigens, including breast cancer antigens, have been described and also given priority ranking for use as vaccine antigens by the US National Cancer Institute. One of the TAA antigens which has been thoroughly examined in numerous trials is Her-2eu. This review will discuss delivery systems for this antigen with special focus on T and B cell peptide vaccines. Attention will be given to their advantages and limitations, as well as the use of certain adjuvants to improve anti-cancer responses. ? 2013 Springer Science+Business Media New York.
机译：对一部分乳腺癌患者的免疫干预代表了一种完善的治疗方法，反映了个性化的治疗方式。因此，靶向治疗与肿瘤相关抗原（TAA），例如Her-2 / neu的单克隆抗体的治疗性给药，代表了癌症治疗的一个里程碑。然而，被动抗体施用遭受若干缺点，包括频率和长时间治疗。在基于针对这些相同靶标产生主动免疫应答的方法中，这些不希望有的东西是可以避免的。直到最近，才将肿瘤相对于其微环境的重要性理解为对创建有效的癌症疫苗至关重要。特别地，免疫系统在抑制或促进肿瘤形成和生长中起重要作用。因此，合适的触发因子的激活（例如Th1细胞，CD8 + T细胞的诱导和调节细胞的抑制以及具有抗肿瘤活性的抗体的产生）是理想的目标。当前的疫苗接种方法集中于使用某些TAA的治疗性疫苗。已经描述了许多癌症抗原，包括乳腺癌抗原，并且还被美国国家癌症研究所（National Cancer Institute）优先用作疫苗抗原。在众多试验中已彻底检查过的TAA抗原之一是Her-2 / neu。这篇综述将讨论这种抗原的递送系统，特别关注T和B细胞肽疫苗。将关注它们的优点和局限性，以及使用某些佐剂改善抗癌反应。 ？ 2013年Springer Science + Business Media纽约。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号